Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod
- 141 Downloads
Fingolimod is an effective therapy for multiple sclerosis (MS). Isolated reports of very aggressive MS rebound after discontinuation of fingolimod are drawing neurologists’ attention to this potentially severe complication of the drug.
Our objective was to collect literature data on cases of MS rebound following fingolimod withdrawal. In addition, we report six new cases of this adverse event in Brazil.
We carried out a systematic review of published data on cases of MS rebound after fingolimod was discontinued. In addition, the study reports a retrospective data series of Brazilian patients presenting this rebound reaction.
Twenty papers have been published reporting on 52 patients with severe MS rebound after fingolimod withdrawal. Six new patients are included in the present paper, all of them with aggressive rebound and accumulated disability sequelae.
We recommend gradual discontinuation of fingolimod with replacement by other treatment. The washout period should not exceed 4 weeks.
Compliance with Ethical Standards
This study received no public or private funding.
Conflict of interest
Yara D. Fragoso, Tarso Adoni, Sidney Gomes, Marcus V. M. Goncalves, Laura F. Parolin, Gleysson Rosa, and Heloisa H. Ruocco have no conflicts of interest to declare.
All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments), with the approval of the Ethics Committee at Universidade Metropolitana de Santos, Santos, SP, Brazil. Patients have given written consent for publication of their clinical data and magnetic resonance images.
- 20.De Masi R, Accoto S, Orlando S, De Blasi V, Pasca S, Scarpello R, et al. Dramatic recovery of steroid-refractory relapsed multiple sclerosis following fingolimod discontinuation using selective immune adsorption. BMC Neurol. 2015;15:125. https://doi.org/10.1186/s12883-015-0377-2.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Vermersch P, Radue EW, Putzki N, Ritter S, Merschhemke M, Freedman MS. A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. Mult Scler J Exp Transl Clin. 2017;3:2055217317730096. https://doi.org/10.1177/2055217317730096.CrossRefPubMedPubMedCentralGoogle Scholar